Vyome Holdings, Inc HIND
Biotechnology: Pharmaceutical Preparations · IPO 2016 · data as of November 13, 2026
Vyome Holdings, Inc (HIND) is a healthcare company listed in the US with a market value of about $11M. In the twelve months to September 30, 2026 it had revenue of $153095 and net income of -$4M, a net margin of -2455.6%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is value (2/5); the weakest is track record (0/5).
Key numbers: a P/E of 0.9, 5-year revenue growth of -51% a year, a 5-year average ROIC of -367%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 99% below the current price.
About Vyome
Vyome is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2016. Revenue went from $3M in 2019 to $319714 in 2025, a decline of about 32.2% a year. It was profitable in 0 of the last 7 years in our data. Its share count rose by 63185811% over three years (dilution for shareholders). It spends 184% of revenue on research and development.
Score: 1.0 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $153095 | $319714 | $8M | $9M | $11M | $14M | $11M | $3M |
| Net income | -$4M | -$10M | -$1M | -$11M | -$46M | -$63M | -$22M | -$24M |
| Free cash flow | — | — | — | -$17M | -$22M | -$16M | -$9M | -$23M |
| EPS (diluted) | $4.58 | $-4.86 | $-6001.39 | $-237181.75 | $-13511071.16 | $-35852104.98 | $-38935395.51 | $-35351090.15 |
| Net margin | -2455.6% | -3209.7% | -18.1% | -131.2% | -411.2% | -464.3% | -191.4% | -721.6% |
| ROIC | — | -217.7% | -111.3% | -175.5% | -1199.7% | -129.2% | -42.9% | -72.7% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 3 analysts is $8.83, 459% above the current price; targets range from $3.50 to $15.00; the consensus rating is “none”; expected EPS is $-0.65 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Vyome’s P/E ratio?
About 0.9, based on the last twelve months of diluted earnings per share.
Is Vyome stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 99% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Vyome pay a dividend?
Not currently.
Is Vyome a good stock to buy?
We do not give buy or sell advice. Vyome scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.